|
US2017275375A1
|
|
Combination therapy with T-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
WO2017210058A1
|
|
Combination therapy with t-cell redirecting bispecific antibodies and checkpoint inhibitors
|
|
US2017166651A1
|
|
Modular Method to Prepare Tetrameric Cytokines with Improved Pharmacokinetics by the Dock-and-Lock (DNL) Technology
|
|
US2017121692A1
|
|
Methods for Generating Stably Linked Complexes Composed of Homodimers, Homotetramers or Dimers of Dimers and Uses
|
|
US2017088635A1
|
|
Dock-and-Lock (DNL) Complexes for Therapeutic and Diagnostic Use
|
|
US2017056516A1
|
|
Tetrameric cytokines with improved biological activity
|
|
US2015231241A1
|
|
Combination therapy for inducing immune response to disease
|
|
US2015132217A1
|
|
Disease therapy by inducing immune response to Trop-2 expressing cells
|
|
WO2015126548A1
|
|
Disease therapy by inducing immune response to trop-2 expressing cells
|
|
EP3062818A1
|
|
Bispecific antibodies that neutralize both tnf-alpha and il-6: novel therapeutic agent for autoimmune disease
|
|
US2015024459A1
|
|
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
|
US2015024458A1
|
|
Dock-and-lock (DNL) complexes for therapeutic and diagnostic use
|
|
US2014099254A1
|
|
Combination therapy for inducing immune response to disease
|
|
WO2014163684A1
|
|
Combination therapy for inducing immune response to disease
|
|
CA2874864A1
|
|
T-cell redirecting bispecific antibodies for treatment of disease
|
|
WO2013181087A2
|
|
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
|
|
US2013136718A1
|
|
Interferon lambada-antibody complexes
|
|
AU2013212000A1
|
|
Targeting interferon-lambda with antibodies potently enhances anti-tumor and anti-viral activities
|
|
WO2013082254A1
|
|
Multivalent antibody complexes targeting igf-1r show potent toxicity against solid tumors
|
|
US2013095033A1
|
|
Multivalent antibody complexes targeting IGF-1R show potent toxicity against solid tumors
|
